Dynavax Technologies Sees Unusually Large Options Volume (NASDAQ:DVAX)

Dynavax Technologies Co. (NASDAQ:DVAX) was the target of some unusual options trading activity on Tuesday. Stock investors purchased 3,017 call options on the company. This is an increase of approximately 803% compared to the average volume of 334 call options.

Dynavax Technologies Trading Down 2.9 %

Shares of DVAX stock opened at $13.58 on Thursday. The company has a market capitalization of $1.68 billion, a PE ratio of 75.44 and a beta of 1.23. Dynavax Technologies has a 52-week low of $9.74 and a 52-week high of $14.63. The business’s fifty day moving average is $13.29 and its 200 day moving average is $12.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23.

Dynavax Technologies (NASDAQ:DVAX) last announced its earnings results on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.05. The business had revenue of $72.03 million for the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a return on equity of 4.22% and a net margin of 9.85%. On average, equities research analysts anticipate that Dynavax Technologies will post 0.32 EPS for the current fiscal year.

Institutional Investors Weigh In On Dynavax Technologies

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Deep Track Capital LP increased its holdings in shares of Dynavax Technologies by 42.0% in the 4th quarter. Deep Track Capital LP now owns 17,791,486 shares of the biopharmaceutical company’s stock worth $227,197,000 after buying an additional 5,265,000 shares during the last quarter. Deerfield Management Company L.P. Series C increased its stake in Dynavax Technologies by 23,990.1% in the fourth quarter. Deerfield Management Company L.P. Series C now owns 5,193,823 shares of the biopharmaceutical company’s stock valued at $66,325,000 after acquiring an additional 5,172,263 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Dynavax Technologies by 4.4% during the fourth quarter. Dimensional Fund Advisors LP now owns 4,067,951 shares of the biopharmaceutical company’s stock valued at $51,948,000 after purchasing an additional 171,933 shares in the last quarter. Renaissance Technologies LLC lifted its stake in Dynavax Technologies by 1.8% during the fourth quarter. Renaissance Technologies LLC now owns 2,355,278 shares of the biopharmaceutical company’s stock worth $30,077,000 after purchasing an additional 41,000 shares during the last quarter. Finally, D. E. Shaw & Co. Inc. boosted its holdings in shares of Dynavax Technologies by 34.0% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,918,340 shares of the biopharmaceutical company’s stock worth $24,497,000 after purchasing an additional 486,981 shares in the last quarter. 96.96% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on DVAX shares. The Goldman Sachs Group lowered Dynavax Technologies from a “neutral” rating to a “sell” rating and cut their price target for the stock from $15.00 to $12.00 in a report on Tuesday, February 11th. StockNews.com upgraded Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday, February 24th. HC Wainwright reiterated a “buy” rating and set a $31.00 price target on shares of Dynavax Technologies in a research report on Friday, February 21st. Finally, William Blair restated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.